Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ovarian Neoplasms

  Free Subscription

Articles published in
Clin Cancer Res
    January 2024
  1. WANG Y, Situ X, Cardenas H, Siu E, et al
    Preclinical evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer.
    Clin Cancer Res. 2024 Jan 17. doi: 10.1158/1078-0432.CCR-23-2368.
    >> Share

    December 2023
  2. TSANG ES, Gallinger S
    Deciphering the Pathways to PARP Sensitivity in Pancreatic Cancer.
    Clin Cancer Res. 2023;29:5005-5007.
    >> Share

  3. BROWN TJ, Yablonovitch A, Till JE, Yen J, et al
    The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib.
    Clin Cancer Res. 2023;29:5207-5216.
    >> Share

  4. WANG Y, Douville C, Chien YW, Wang BG, et al
    Aneuploidy Landscape in Precursors of Ovarian Cancer.
    Clin Cancer Res. 2023 Dec 1. doi: 10.1158/1078-0432.CCR-23-0932.
    >> Share

    November 2023
  5. DREW Y, Kim JW, Penson RT, O'Malley DM, et al
    Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naive Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
    Clin Cancer Res. 2023 Nov 8. doi: 10.1158/1078-0432.CCR-23-2249.
    >> Share

  6. SOBERANIS PINA P, Oza AM
    Methodical Manipulation of the TME in Ovarian Cancer.
    Clin Cancer Res. 2023 Nov 8. doi: 10.1158/1078-0432.CCR-23-2365.
    >> Share

    October 2023
  7. BUCKLEY DN, Lewinger JP, Gooden G, Spillman M, et al
    OvaPrint - a cell-free DNA methylation liquid biopsy for the risk assessment of high-grade serous ovarian cancer.
    Clin Cancer Res. 2023 Oct 9. doi: 10.1158/1078-0432.CCR-23-1197.
    >> Share

    September 2023
  8. JAMIESON A, Vermij L, Kramer CJH, Jobsen JJ, et al
    Clinical Behavior and Molecular Landscape of Stage I p53-abnormal Low-Grade Endometrioid Endometrial Carcinomas.
    Clin Cancer Res. 2023 Sep 29. doi: 10.1158/1078-0432.CCR-23-1397.
    >> Share

  9. LEMAN R, Muller E, Legros A, Goardon N, et al
    Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer.
    Clin Cancer Res. 2023 Sep 26:OF1-OF11. doi: 10.1158/1078-0432.CCR-23-0898.
    >> Share

    August 2023
  10. GRISHAM RN, Vergote I, Banerjee S, Drill E, et al
    Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.
    Clin Cancer Res. 2023 Aug 15:CCR-23-0621. doi: 10.1158/1078-0432.CCR-23-0621.
    >> Share

  11. TAVIRA B, Iscar T, Manso L, Santaballa A, et al
    Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).
    Clin Cancer Res. 2023 Aug 1:CCR-23-0771. doi: 10.1158/1078-0432.CCR-23-0771.
    >> Share

    July 2023
  12. DOE-TETTEH SA, Camp SY, Reales D, Crowdis J, et al
    Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach.
    Clin Cancer Res. 2023;29:2445-2455.
    >> Share

    June 2023
  13. GARG V, Oza AM
    Assessment of Homologous Recombination Deficiency in Ovarian Cancer.
    Clin Cancer Res. 2023 Jun 22:CCR-23-0563. doi: 10.1158/1078-0432.CCR-23-0563.
    >> Share

  14. HEINZE K, Cairns ES, Thornton S, Harris B, et al
    The prognostic effect of immune cell infiltration depends on molecular subtype in Endometrioid Ovarian Carcinomas.
    Clin Cancer Res. 2023 Jun 20:CCR-22-3815. doi: 10.1158/1078-0432.CCR-22-3815.
    >> Share

  15. LHEUREUX S, Prokopec SD, Oldfield LE, Gonzalez-Ochoa E, et al
    Identifying mechanisms of resistance by circulating tumour DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at time of PARP Inhibitor Progression.
    Clin Cancer Res. 2023 Jun 16:CCR-23-0797. doi: 10.1158/1078-0432.CCR-23-0797.
    >> Share

    May 2023
  16. DILAWARI A, Shah M, Ison G, Gittleman H, et al
    FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRalpha-positive, Platinum-Resistant Ovarian Cancer.
    Clin Cancer Res. 2023 May 22:CCR-23-0991. doi: 10.1158/1078-0432.CCR-23-0991.
    >> Share

  17. GONZALEZ-OCHOA E, Oza AM
    An attempt to stretch the benefit: Re-challenge with PARP inhibitors in ovarian cancer.
    Clin Cancer Res. 2023 May 16:CCR-23-0652. doi: 10.1158/1078-0432.CCR-23-0652.
    >> Share

  18. DORIGO O, Oza AM, Pejovic T, Ghatage P, et al
    Maveropepimut-S, a DPX-based immune-educating therapy, shows promising and durable clinical benefit in patients with recurrent ovarian cancer, a phase 2 trial.
    Clin Cancer Res. 2023 May 1:CCR-22-2595. doi: 10.1158/1078-0432.CCR-22-2595.
    >> Share

    April 2023
  19. COMPADRE AJ, van Biljon LN, Valentine MC, Llop-Guevara A, et al
    RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer.
    Clin Cancer Res. 2023 Apr 25:CCR-22-3335. doi: 10.1158/1078-0432.CCR-22-3335.
    >> Share

  20. WETHINGTON SL, Shah PD, Martin L, Tanyi JL, et al
    Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer.
    Clin Cancer Res. 2023 Apr 25:CCR-22-2444. doi: 10.1158/1078-0432.CCR-22-2444.
    >> Share

  21. BLANC-DURAND F, Tang R, Pommier M, Nashvi M, et al
    Clinical relevance of BRCA1 promoter methylation testing in ovarian cancer patients.
    Clin Cancer Res. 2023 Apr 17:CCR-22-3328. doi: 10.1158/1078-0432.CCR-22-3328.
    >> Share

  22. KIM YN, Shim Y, Seo J, Choi Z, et al
    Investigation of poly ADP-ribose polymerase inhibitor resistance based on serially collected circulating tumor DNA in patients with BRCA-mutated ovarian cancer.
    Clin Cancer Res. 2023 Apr 17:CCR-22-3715. doi: 10.1158/1078-0432.CCR-22-3715.
    >> Share

  23. LIU YL, Zamarin D
    Shedding Light on PARP Inhibitor Response through Functional Imaging.
    Clin Cancer Res. 2023;29:1384-1386.
    >> Share

    March 2023
  24. BATALINI F, Mina LA, Mina A
    Therapy-related Myeloid Neoplasms Following PARP Inhibitors-Letter.
    Clin Cancer Res. 2023;29:1157.
    >> Share

  25. MARMOUSET V, Morice PM, Pages A, Leary A, et al
    Therapy-related Myeloid Neoplasms Following PARP Inhibitors-Response.
    Clin Cancer Res. 2023;29:1158-1159.
    >> Share

    February 2023
  26. AL-RAWI DH, Rusk N, Friedman CF
    The Search for Genomic Biomarkers of Response to Immunotherapy in Ovarian Cancer.
    Clin Cancer Res. 2023 Feb 24:CCR-23-0048. doi: 10.1158/1078-0432.CCR-23-0048.
    >> Share

  27. PIKKUSAARI S, Tumiati M, Virtanen A, Oikkonen J, et al
    Functional homologous recombination assay on FFPE specimens of advanced high-grade serous ovarian cancer predicts clinical outcomes.
    Clin Cancer Res. 2023 Feb 20:CCR-22-3156. doi: 10.1158/1078-0432.CCR-22-3156.
    >> Share

  28. MORGAN RD, Clamp AR, White DJ, Price M, et al
    Multi-maintenance olaparib therapy in relapsed, germline BRCA1/2-mutant high-grade serous ovarian cancer (MOLTO): a phase II trial.
    Clin Cancer Res. 2023 Feb 17:CCR-22-3282. doi: 10.1158/1078-0432.CCR-22-3282.
    >> Share

  29. COLE AJ, Panesso-Gomez S, Shah JS, Ebai T, et al
    Quiescent ovarian cancer cells secrete follistatin to induce chemotherapy resistance in surrounding cells in response to chemotherapy.
    Clin Cancer Res. 2023 Feb 16:CCR-22-2254. doi: 10.1158/1078-0432.CCR-22-2254.
    >> Share

    January 2023
  30. GREEN DS, Ning F, Duemler A, Myers TG, et al
    Correction: Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial.
    Clin Cancer Res. 2023;29:501.
    >> Share

  31. WAINBERG ZA, Singh AS, Konecny GE, McCann KE, et al
    Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy.
    Clin Cancer Res. 2023;29:40-49.
    >> Share

  32. LANDEN CN, Molinero L, Hamidi H, Sehouli J, et al
    Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.
    Clin Cancer Res. 2023 Jan 3:CCR-22-2032. doi: 10.1158/1078-0432.CCR-22-2032.
    >> Share

    December 2022
  33. MARMOUSET V, Decroocq J, Garciaz S, Etienne G, et al
    Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.
    Clin Cancer Res. 2022;28:5211-5220.
    >> Share

    November 2022
  34. PANTEL AR, Gitto SB, Makvandi M, Kim H, et al
    [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a pilot study.
    Clin Cancer Res. 2022 Nov 28:CCR-22-1602. doi: 10.1158/1078-0432.CCR-22-1602.
    >> Share

  35. CHOW S, Dorigo O
    Monocytes - A Promising New TRAIL in Ovarian Cancer Cell Therapy.
    Clin Cancer Res. 2022 Nov 16. pii: 710895. doi: 10.1158/1078-0432.CCR-22-2877.
    >> Share

    October 2022
  36. VENEZIANI AC, Oza AM
    Taking the Road Less Traveled: Following Molecular Trail Markers.
    Clin Cancer Res. 2022;28:4357-4359.
    >> Share

  37. MEAGHER NS, Gorringe KL, Wakefield MJ, Bolithon A, et al
    Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes.
    Clin Cancer Res. 2022 Oct 12. pii: 709665. doi: 10.1158/1078-0432.CCR-22-1206.
    >> Share

    September 2022
  38. GREEN DS, Ning F, Duemler A, Myers TG, et al
    Intraperitoneal monocytes and interferons as a novel cellular immunotherapy for ovarian cancer: mechanistic characterization and results of a phase I clinical trial.
    Clin Cancer Res. 2022 Sep 13. pii: 709187. doi: 10.1158/1078-0432.CCR-22-1893.
    >> Share

  39. LHEUREUX S
    Multi-omics uncovering different faces of Clear Cell Ovarian Cancer.
    Clin Cancer Res. 2022 Sep 12. pii: 709169. doi: 10.1158/1078-0432.CCR-22-2365.
    >> Share

  40. BATALINI F, Gulhan DC, Mao V, Tran A, et al
    Mutational signature 3 detected from clinical panel sequencing is associated with responses to olaparib in breast and ovarian cancers.
    Clin Cancer Res. 2022 Sep 1. pii: 708955. doi: 10.1158/1078-0432.CCR-22-0749.
    >> Share

    August 2022
  41. IRAJIZAD E, Han CY, Celestino J, Wu R, et al
    A blood-based metabolite panel for distinguishing ovarian cancer from benign pelvic masses.
    Clin Cancer Res. 2022 Aug 29. pii: 708818. doi: 10.1158/1078-0432.CCR-22-1113.
    >> Share

  42. WIMBERGER P, Gerber MJ, Pfisterer J, Erdmann K, et al
    Bevacizumab may differentially improve prognosis of advanced ovarian cancer patients with low expression of VEGF-A165b, an anti-angiogenic VEGF-A splice variant.
    Clin Cancer Res. 2022 Aug 24. pii: 708584. doi: 10.1158/1078-0432.CCR-22-1326.
    >> Share

  43. BANERJEE S, Michalarea V, Ang JE, Ingles Garces A, et al
    A phase I trial of CT900, a novel alpha-folate receptor-mediated thymidylate synthase inhibitor, with expansion cohorts in patients with high grade serous ovarian cancer.
    Clin Cancer Res. 2022 Aug 19. pii: 708154. doi: 10.1158/1078-0432.CCR-22-1268.
    >> Share

  44. SERRA V, Wang AT, Castroviejo-Bermejo M, Polanska UM, et al
    Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance.
    Clin Cancer Res. 2022 Aug 3. pii: 707431. doi: 10.1158/1078-0432.CCR-22-0568.
    >> Share

  45. LEE JM, Moore RG, Ghamande S, Park MS, et al
    Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation and with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.
    Clin Cancer Res. 2022 Aug 2. pii: 707411. doi: 10.1158/1078-0432.CCR-21-1733.
    >> Share

    July 2022
  46. BOLTON KL, Chen D, Corona de la Fuente RI, Fu Z, et al
    Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes.
    Clin Cancer Res. 2022 Jul 11. pii: 706955. doi: 10.1158/1078-0432.CCR-21-3817.
    >> Share

  47. FISHER NC, Byrne RM, Leslie H, Wood C, et al
    Biological misinterpretation of transcriptional signatures in tumour samples can unknowingly undermine mechanistic understanding and faithful alignment with preclinical data.
    Clin Cancer Res. 2022 Jul 6. pii: 706888. doi: 10.1158/1078-0432.CCR-22-1102.
    >> Share

    June 2022
  48. JOHNSON M, Dudek AZ, Sukari A, Call J, et al
    ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study.
    Clin Cancer Res. 2022;28:2517-2526.
    >> Share

  49. HOLLIS RL, Meynert AM, Michie CO, Rye T, et al
    Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratification.
    Clin Cancer Res. 2022 Jun 13. pii: 704888. doi: 10.1158/1078-0432.CCR-22-0368.
    >> Share

  50. XU J, Fang Y, Chen K, Li S, et al
    Single-cell RNA sequencing reveals the tissue architecture in human high-grade serous ovarian cancer.
    Clin Cancer Res. 2022 Jun 8. pii: 704811. doi: 10.1158/1078-0432.CCR-22-0296.
    >> Share

  51. BYCHKOVSKY BL, Li T, Sotelo J, Tayob N, et al
    Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program.
    Clin Cancer Res. 2022;28:2349-2360.
    >> Share

  52. NICUM S, Blagden SP
    PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials.
    Clin Cancer Res. 2022;28:2201-2203.
    >> Share

    May 2022
  53. ARANDA F, Eguren-Santamaria I, Bella A, Berraondo P, et al
    Revisiting Intracavitary Immunotherapy of Cancer.
    Clin Cancer Res. 2022;28:1993-1995.
    >> Share

  54. FUCIKOVA J, Hensler M, Kasikova L, Lanickova T, et al
    An autologous dendritic cell vaccine promotes anticancer immunity in ovarian cancer patients with low mutational burden and cold tumors.
    Clin Cancer Res. 2022 May 10. pii: 696491. doi: 10.1158/1078-0432.CCR-21-4413.
    >> Share

    April 2022
  55. YANG SYC, Pugh TJ, Oza AM
    Double trouble: whole genome doubling distinguishes early from late ovarian cancer.
    Clin Cancer Res. 2022 Apr 27. pii: 694785. doi: 10.1158/1078-0432.CCR-22-0336.
    >> Share

  56. LIU M, Tayob N, Penter L, Sellars M, et al
    Improved T cell immunity following neoadjuvant chemotherapy in ovarian cancer.
    Clin Cancer Res. 2022 Apr 20. pii: 694633. doi: 10.1158/1078-0432.CCR-21-2834.
    >> Share

  57. MANNING-GEIST B, Gordhandas S, Liu YL, Zhou Q, et al
    MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma.
    Clin Cancer Res. 2022 Apr 20. pii: 694634. doi: 10.1158/1078-0432.CCR-21-4183.
    >> Share

  58. CHENG Z, Mirza H, Ennis DP, Smith P, et al
    The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma.
    Clin Cancer Res. 2022 Apr 10:OF1-OF12. doi: 10.1158/1078-0432.CCR-21-1643.
    >> Share

  59. AREND RC, Scalise CB, Gordon ER, Davis AM, et al
    Metabolic Alterations and WNT Signaling Impact Immune Response in HGSOC.
    Clin Cancer Res. 2022;28:1433-1445.
    >> Share

    February 2022
  60. DIGKLIA A, Coukos G, Homicsko K
    Trabectedin and Durvalumab Combination is Feasible - and Active in Relapsing Ovarian Cancer.
    Clin Cancer Res. 2022 Feb 17. pii: 681578. doi: 10.1158/1078-0432.CCR-21-4592.
    >> Share

  61. GAO Q, Zhu J, Zhao W, Huang Y, et al
    Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA).
    Clin Cancer Res. 2022 Feb 7. pii: 1078-0432.CCR-21-3023.
    >> Share

    January 2022
  62. ORR B, Mahdi H, Fang Y, Strange M, et al
    Phase I trial combining chemokine-targeting with loco-regional chemo-immunotherapy for recurrent, platinum-sensitive ovarian cancer shows induction of CXCR3 ligands and markers of type 1 immunity.
    Clin Cancer Res. 2022 Jan 19. pii: 1078-0432.CCR-21-3659.
    >> Share

  63. VOUGIOUKLAKIS T, Zhu K, Vasudevaraja V, Serrano J, et al
    Integrated analysis of ovarian juvenile granulosa cell tumors reveals distinct epigenetic signatures and recurrent TERT rearrangements.
    Clin Cancer Res. 2022 Jan 14. pii: 1078-0432.CCR-21-3394.
    >> Share

    December 2021
  64. TOULMONDE M, Brahmi M, Giraud A, Chakiba C, et al
    Trabectedin plus durvalumab in patients with advanced pretreated soft tissue sarcoma and ovarian carcinoma (TRAMUNE): an open-label, multicenter phase Ib study.
    Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-2258.
    >> Share

  65. SHARMA SK, Mack KN, Piersigilli A, Pourat J, et al
    ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody.
    Clin Cancer Res. 2021 Dec 14. pii: 1078-0432.CCR-21-1798.
    >> Share

    November 2021
  66. WU X, Zhu J, Wang J, Lin ZQ, et al
    Pamiparib Monotherapy for Patients With Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated With at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study.
    Clin Cancer Res. 2021 Nov 29. pii: 1078-0432.CCR-21-1186.
    >> Share

  67. VAN DER WIJNGAART H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, et al
    Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types.
    Clin Cancer Res. 2021;27:6106-6114.
    >> Share

    October 2021
  68. TIAN L, Xu B, Teng KY, Song M, et al
    Targeting Fc receptor-mediated effects and the "don't eat me" signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer.
    Clin Cancer Res. 2021 Oct 13. pii: 1078-0432.CCR-21-1248.
    >> Share

  69. MOORE KN, Chambers SK, Hamilton EP, Chen LM, et al
    Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: an Open-Label, Four-Arm, Phase II Study.
    Clin Cancer Res. 2021 Oct 13. pii: 1078-0432.CCR-21-0158.
    >> Share

    September 2021
  70. SCHOUTEN PC, Richters LK, Vis DJ, Kommoss S, et al
    Ovarian cancer specific BRCA-like copy number aberration classifiers detect mutations associated with homologous recombination deficiency in the AGO-TR1 trial.
    Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-1673.
    >> Share

  71. CECIL DL, Liao JB, Dang Y, Coveler AL, et al
    Immunization with a plasmid DNA vaccine encoding the N-terminus of Insulin like Growth Factor Binding Protein-2 in advanced ovarian cancer leads to high level Type I immune responses.
    Clin Cancer Res. 2021 Sep 15. pii: 1078-0432.CCR-21-1579.
    >> Share

  72. WESTIN SN, Labrie M, Litton JK, Blucher A, et al
    Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer.
    Clin Cancer Res. 2021 Sep 13. pii: 1078-0432.CCR-21-1656.
    >> Share

  73. DO KT, Kochupurakkal B, Kelland S, de Jonge A, et al
    Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
    Clin Cancer Res. 2021;27:4710-4716.
    >> Share

    August 2021
  74. MAITLAND ML, Sachdev JC, Sharma MR, Moreno V, et al
    First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
    Clin Cancer Res. 2021;27:4511-4520.
    >> Share

  75. SZTUPINSZKI Z, Diossy M, Borcsok J, Prosz A, et al
    Comparative Assessment of Diagnostic Homologous Recombination Deficiency associated mutational signatures in ovarian cancer.
    Clin Cancer Res. 2021 Aug 11. pii: 1078-0432.CCR-21-0981.
    >> Share

  76. KAMAT AA, Fletcher M, Gruman LM, Mueller P, et al
    Editor's Note: The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer.
    Clin Cancer Res. 2021;27:4455.
    >> Share

    July 2021
  77. THAKER PH, Bradley WH, Leath CA, Gunderson Jackson C, et al
    GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-Escalation Study.
    Clin Cancer Res. 2021 Jul 29. pii: 1078-0432.CCR-21-0360.
    >> Share

    May 2021
  78. KANDIMALLA R, Wang W, Yu F, Zhou N, et al
    OCaMIR - A noninvasive, diagnostic signature for early stage ovarian cancer: a multi-cohort retrospective and prospective study.
    Clin Cancer Res. 2021 May 25. pii: 1078-0432.CCR-21-0267.
    >> Share

  79. MIAO YR, Thakkar KN, Qian J, Kariolis MS, et al
    Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer.
    Clin Cancer Res. 2021 May 19. pii: 1078-0432.CCR-20-0482.
    >> Share

  80. LAUMONT CM, Wouters MCA, Smazynski J, Gierc NS, et al
    Single-cell profiles and prognostic impact of tumor-infiltrating lymphocytes co-expressing CD39, CD103, and PD-1 in ovarian cancer.
    Clin Cancer Res. 2021 May 7. pii: 1078-0432.CCR-20-4394.
    >> Share

    March 2021
  81. THIBODEAUX S, Barnett B, Pandeswara S, Wall S, et al
    Interferon-alpha augments clinical efficacy of regulatory T cell depletion with denileukin diftitox in ovarian cancer.
    Clin Cancer Res. 2021 Mar 26. pii: 1078-0432.CCR-20-4594.
    >> Share

  82. KAZMI F, Nicum S, Roux RL, Spiers L, et al
    A Phase IB open-label, dose-escalation study of NUC1031 in combination with carboplatin for recurrent ovarian cancer.
    Clin Cancer Res. 2021 Mar 19. pii: 1078-0432.CCR-20-4403.
    >> Share

  83. EWING A, Meynert A, Churchman M, Grimes G, et al
    Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma.
    Clin Cancer Res. 2021 Mar 19. pii: 1078-0432.CCR-20-4068.
    >> Share

    February 2021
  84. LI N, Bu H, Liu J, Zhu J, et al
    An open-label, multi-center, single-arm, phase 2 study of fluzoparib in patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian cancer.
    Clin Cancer Res. 2021 Feb 8. pii: 1078-0432.CCR-20-3546.
    >> Share

    January 2021
  85. HONG B, Chapa V, Saini U, Modgil P, et al
    Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity.
    Clin Cancer Res. 2021;27:542-553.
    >> Share

  86. HU Z, Cunnea P, Zhong Z, Lu H, et al
    The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers.
    Clin Cancer Res. 2021 Jan 14. pii: 1078-0432.CCR-20-2782.
    >> Share

    December 2020
  87. PARACCHINI L, Beltrame L, Grassi T, Inglesi A, et al
    Genome-wide copy number alterations in circulating tumor DNA as a novel biomarker in high grade serous ovarian cancer patients.
    Clin Cancer Res. 2020 Dec 15. pii: 1078-0432.CCR-20-3345.
    >> Share

    September 2020
  88. ISHAK CA, De Carvalho DD
    DNA methylation profiling of premalignant lesions as a path to ovarian cancer early detection.
    Clin Cancer Res. 2020 Sep 28. pii: 1078-0432.CCR-20-3331.
    >> Share

    December 2019
  89. LI F, Zhang Z, Cai J, Chen X, et al
    Primary preclinical and clinical Evaluation of 68Ga-DOTA-TMVP1 as a novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer.
    Clin Cancer Res. 2019 Dec 16. pii: 1078-0432.CCR-19-1845.
    >> Share

    October 2019
  90. SOLIMAN PT, Westin SN, Iglesias DA, Fellman BM, et al
    Everolimus, letrozole, and metformin in women with advanced or recurrent endometrioid endometrial cancer: A multi-center, single arm, phase II study.
    Clin Cancer Res. 2019 Oct 18. pii: 1078-0432.CCR-19-0471.
    >> Share

  91. MCCLOSKEY CW, Cook DP, Kelly BS, Azzi F, et al
    Metformin abrogates age-associated ovarian fibrosis.
    Clin Cancer Res. 2019 Oct 9. pii: 1078-0432.CCR-19-0603.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016